Таргетные препараты в детской онкологии

T. T. Valiev, A. S. Levashov, E. R. Senzhapova

Аннотация


Фундаментальные исследования в области молекулярной биологии, иммунологии, цитогенетики и эпигенетики опухолевой клетки позволили не только определить основные молекулярные пути злокачественной трансформации, но и модифицировать их с помощью таргетных препаратов (ТП). По мере расширения наших представлений о молекулярно-биологических основах онкогенеза расширяется спектр мишеней для таргетной терапии, блокирующей ангиогенез, сигнальные пути, потенциально онкогенные белки и ферменты. В настоящее время ТП стали неотъемлемой частью стандартов терапии взрослых больных со злокачественными опухолями.

Роль и место ТП в лечении детей со злокачественными опухолями продолжают изучаться. Проводятся работы, определяющие побочные эффекты ТП у детей, анализируются результаты стандартных химиотерапевтических подходов и протоколов терапии с включением таргетных агентов. В настоящей статье обобщен современный мировой опыт применения ТП в детской онкологии, выделены показания и режимы введения ТП, определены перспективы дальнейших исследований в индивидуализации химиотерапевтического лечения детей со злокачественными новообразованиями на основании молекулярного «портрета» опухоли.


Ключевые слова


таргетная терапия; злокачественные опухоли; дети

Полный текст:

PDF

Литература


Ko JJ, Bernard B, Tran B, et al. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. J Clin Oncol. 2016;34(7):714−20.

Валиев Т.Т., Барях Е.А., Зейналова П.А. и соавт. Оптимизация диагностики и лечения лимфомы Беркитта у детей, подростков и молодых взрослых. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2014;7(2):175−183.

Иммунотерапия. Руководство для врачей под ред. академика РАН и РАМН Р.М. Хаитова, проф. Р.И. Атауллаханова. М.: ГОЭТАР-Медиа. 2012. 669 с.

Владимирская Е.Б. Механизмы кроветворения и лейкемогенеза. Цикл лекций. М.: Династия. 2007. 150 с.

Программное лечение заболеваний системы крови. Т. II. Под ред. В.Г. Савченко. М.: Практика. 2012. 1052 с.

Руководство по химиотерапии опухолевых заболеваний под ред. Н.И. Переводчиковой. М.: Практическая медицина. 2011. 510 с.

Лейкозы у детей. Под ред. Г.Л. Менкевича, С.А. Маяковой. М.: Практическая медицина. 2009. 381 с.

Ganta RR, Nasaka S, Gundeti S. Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia ― Chronic Phase. Indian J Pediatr. 2016 Feb 3. [Epub ahead of print].

Giona F, Putti MC, Micalizzi C, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015;170(3):398−407.

Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936−45.

Guo Y, Liu T.F, Ruan M, et al. Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(8):819−24.

Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114(27):5426−35.

Al-Jafar HA, Al-Mulla A, AlDallal S, et al. Successful nilotinib treatment in a child with chronic myeloid leukemia. Case Rep Oncol. 2015;8(1):122−7.

Müller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944−53.

Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program. 2010;2010:368−76.

Луговская С.А., Почтарь М.Е., Тупицын Н.Н. Иммунофенотипирование в диагностике гемобластозов. М.: Триада. 2005. 165 с.

Курильников А.Я. Мабтера ― первые моноклональные антитела в терапии неходжкинских лимфом. Совр. онкол. 2002;4(1):25−28.

Reff M, Carner C, Chambers K, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435−445.

Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs. 2007;67(3):333−50.

Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol. 2007;67:5−14.

Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs. 2003;63(8):803−843.

Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia. J Clin Oncol. 2010;28(19):3115−3121.

Bilic E, Femenic R, Conja J, et al. CD20-positive childhood B-non-Hodgkin lymphoma: morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol. 2010;34(1):171−175.

Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. и др. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004м с применением ритуксимаба и модифицированного протокола В-НХЛ ВФМ 90. Онкогематол. 2009;3:4−14.

Валиев Т.Т., Морозова О.В., Попа А.В. и соавт. Результаты лечения лимфомы Беркитта у детей. Гематология и трансфузиология. 2012;57(3, Прил.):34.

Hamedani FS, Cinar M, Mo Z, et al. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. Leuk Res. 2014;38(4):503−8.

Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):378.

Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472−80.

Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190−6.

Mikles B, Levine J, Gindin T, et al. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J Pediatr Hematol Oncol. 2014;36(2):85−7.

Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J. 2012;18(5):450−6.

Eyre TA, Khan D, Hall GW, et al. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol. 2014;93(6):455−68.

Kelly KM, Hodgson D, Appel B, et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013;60(6):972−8.

Accardi F, Toscani D, Bolzoni M, et al. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. Biomed Res Int. 2015. Р. 1−13.

Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21(37):5673−83.

Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639−47.

Horton TM, Drachtman RA, Chen L, et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015;170(1):118−22.

Du XL, Chen Q. Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematol. 2013;129(4):207−14.

Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285−90.

Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254−9.

Boye K, Del Prever AB, Eriksson M, et al. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer. 2014;61(5):840−5.

Ebb D, Holcombe G, Karen M, et al. Phase II Trial of Trastuzumab in Combination with Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma with Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 2012;30(20): 2245−2551.

Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407−14.

Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508−16.

Mei J, Zhu X, Wang Z, et al. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment. Cell Biochem Biophys. 2014;69(1):151−6.

Pignochino Y, Dell'Aglio C, Basiricò M, et al The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117−31.

Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98−107.

Grignani G, Palmerini E, Dileo P, et al. A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 2012;18(21): 6011–6022.

Hiroto I, Rubnitz JE, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology. 2011;29(24):3293−3300.

Schmid I, Häberle B, Albert MH, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 2012;58(4):539−44.

Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007;25(30):4806−12.

Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19(22):6305−12.

Gottardo NG, Hansford JR, McGlade JP, et al Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014;127(2):189−201.

Robinson GW, Orr BA, Wu G, et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33(24):2646−54.

Wetmore C, Boyett J, Li S, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol. 2015;17(6):882−8.

DuBois SG, Marachelian A, Fox E, et al. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Feb 16.

Qaddoumi I, Kocak M, Pai Panandiker AS, et al. Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. Front Oncol. 2014;4:67.

Hummel TR, Salloum R, Drissi R, et al. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neurooncol. 2016;127(1):53−61.

Fouladi M, Stewart CF, Blaney SM, et al. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal Neurooncology. 2013;114(2):173−9.




DOI: http://dx.doi.org/10.15690/onco.v3i1.1524

Ссылки

  • На текущий момент ссылки отсутствуют.